Clinical Trial Update: A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial CM310 in moderate-to-severe Atopic Dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CM310

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED